Home

JULIAN ADAMS

CIK 1230486 · Chief Executive Officer · last filed 2026-09-02

JULIAN ADAMS is a Chief Executive Officer who has filed 25 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for ELTX, was dated Sep 2, 2026. 4 SEC filings were submitted jointly with PALVELLA THERAPEUTICS, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

4

Total Filings

25

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
C/O GAMIDA CELL
673 BOYLSTON STREET, 4TH FLOOR
BOSTON, MA 02116
Related Filers
PALVELLA THERAPEUTICS, INC. — 4 joint filings, latest 2018-01-29
MILLENNIUM PHARMACEUTICALS INC — 3 joint filings, latest 2003-09-03
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ELTX Director — $2.41 — $0 4 2026-09-02
Gamida Cell Ltd. (GMDA) Delisted Chief Executive Officer 423,750 $0.03 $13.9K $0 5 2024-02-02
PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Director — $13.60 — $0 3 2018-01-29
INFINITY PHARMACEUTICALS, INC. (INFI) Delisted President of R&D 322,095 $0.04 $14.4K $0 13 2016-11-02

Recent Filings

25 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-02 ELTX Grant (A) — $0 EDGAR
2025-05-20 ELTX Grant (A) — $0 EDGAR
2024-11-25 ELTX Grant (A) — $0 EDGAR
2024-02-02 Gamida Cell Ltd. (GMDA) Delisted Grant (A) +200,000 $0 EDGAR
2023-12-29 ELTX Grant (A) — $0 EDGAR
2023-10-20 Gamida Cell Ltd. (GMDA) Delisted Grant (A) +28,300 $0 EDGAR
2023-02-10 Gamida Cell Ltd. (GMDA) Delisted Grant (A) +28,300 $0 EDGAR
2022-11-22 Gamida Cell Ltd. (GMDA) Delisted Grant (A) +2,000 $0 EDGAR
2022-08-10 Gamida Cell Ltd. (GMDA) Delisted Grant (A) +117,300 $0 EDGAR
2018-01-29 PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 25
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.